Mink Therapeutics

INKT · NASDAQ

$9.86+$0.30 (+3.14%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $9.56

INKT analyst rating

BuyConsensus of 1 analyst over the last 12 months. 100% rate it a buy.

Strong buy0
Buy1
Hold0
Underperform0
Sell0

12-month price target · 4 analysts

Average $39.78 (+303.4% upside)

Low: $35.35
Now: $9.86
High: $45.15

Upgrades and downgrades

The latest rating actions, newest first

INKT analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
HC Wainwright & Co.	May 18, 2026	Maintains	Buy	$35.00	27%
HC Wainwright & Co.	Apr 1, 2026	Maintains	Buy	$35.00	27%

The case for and against

Updated Sep 16, 2026

Bull case

MiNK Therapeutics is well-positioned in the fast-growing field of allogeneic iNKT cell therapy, which offers distinct advantages over traditional therapies for cancer and other immune-mediated diseases. With a strong pipeline of innovative products, including the promising agenT-797, and a focus on single segment operations, the company has a solid foundation for future success. While additional financing may be needed in the coming years, the company's cash runway into late 2026/early 2027 and strong intellectual property protection provide reassurance for long-term investors.

Bear case

MiNK Therapeutics is facing decreased operating expenses and has a low cash balance, which may hinder its ability to advance its product candidate agenT-797 in its clinical trials. Additionally, the company’s reliance on external funding for its Phase 2 trials may not lead to significant R&D expenses, limiting its ability to effectively develop and bring its product to market. With a lowered discount rate, the company may have more financial flexibility, but the uncertainty surrounding its product and funding sources leads to a negative outlook on its stock.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.